Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kyoko Hongo
Observed name:
K. Hongo
Institution:
National Cancer Center Hospital East
Observed institution:
National Cancer Center Hospital East
ORCID:
0009-0004-3781-9965
Observed ORCID:
0009-0004-3781-9965
OpenAlex ID:
A5049062478
Neoadjuvant combination treatment of olaparib and pembrolizumab for patients with HRD-positive advanced ovarian cancer.
2024
·
Kenichi Harano
, Takehiro Nakao
, et al.
·
Journal of Clinical Oncology
·
9
PDF
Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
2026
·
Kenichi Harano
, Takehiro Nakao
, et al.
·
Clinical Cancer Research
·
6
534P A pilot study of neoadjuvant olaparib for patients with HRD-positive advanced ovarian cancer
2022
·
K. Harano
, T. Nakao
, et al.
·
Annals of Oncology
·
4
Longitudinal remodeling of the tumor-immune microenvironment during regorafenib, nivolumab, and chemotherapy in advanced gastric cancer
2026
·
Kota Itahashi
, Akihito Kawazoe
, et al.
·
Science Translational Medicine
Supplementary Figure S5 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
2026
·
Kenichi Harano
, Takehiro Nakao
, et al.
Supplementary Figure S1 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
2026
·
Kenichi Harano
, Takehiro Nakao
, et al.
Data from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
2026
·
Kenichi Harano
, Takehiro Nakao
, et al.
Supplementary Figure S4 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
2026
·
Kenichi Harano
, Takehiro Nakao
, et al.
Supplementary Table S1 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
2026
·
Kenichi Harano
, Takehiro Nakao
, et al.
Supplementary Figure S2 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
2026
·
Kenichi Harano
, Takehiro Nakao
, et al.
Supplementary Figure S3 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
2026
·
Kenichi Harano
, Takehiro Nakao
, et al.
Supplementary Table S2 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
2026
·
Kenichi Harano
, Takehiro Nakao
, et al.
First-line regorafenib with nivolumab and FOLFOX or CapeOX in patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: A single-arm, phase Ib/II trial (REGONIVOCTx, EPOC2104).
2024
·
Akihito Kawazoe
, Tadayoshi Hashimoto
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
13
Citation count:
19
H-index:
3
I10-index:
Year
Topic
Type